Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT595 in adults with chronic primary immune thrombocytopenia
2015-003653-17Phase 3Completed
- Sponsor
- Biotest AG
- Start
- Jun 2016
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of KIg10 in immune thrombocytopenia (ITP) (2 arms), sponsored by Biotest AG. Primary endpoint: Rate of subjects with response. Started Jun 2016; status: completed.
02
Drugs
KIg10
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2015-003653-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003653-17.